Indian pharmaceutical industry leaders are advocating for a renewed focus on compliance and quality-first manufacturing to bolster the country's reputation as the 'pharmacy of the world'. This follows increased international scrutiny after incidents of contaminated drugs from India were linked to fatalities overseas.
In recent years, regulatory bodies like the US FDA have issued numerous observations and import alerts for Indian manufacturing facilities. Industry experts state that moving beyond cost competitiveness to unwavering quality standards is critical for long-term growth and trust.
The government has responded with initiatives like the revised Schedule M of the Drugs and Cosmetics Rules, which mandates higher Good Manufacturing Practice (GMP) standards aligned with global norms. Investments in advanced manufacturing technologies and robust quality management systems are now seen as essential for market access.
By prioritizing compliance, the industry aims to secure its position in key markets like the US, Europe, and Africa, while also catering to rising domestic demand for high-quality medicines. The shift is viewed as a necessary evolution for sustainable leadership in the global generics market.
